Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development · broad
The model's full reasoning — Q4 2023 call → NOWe need to evaluate the transcript for two gates. Gate 1: Is there a positive current development with Q&A adding concrete operating detail beyond prepared remarks? Gate 2: Is that development broad and granular demand base, not concentrated? Let's analyze the transcript. The call is a "Learnings Call" by Recursion Pharmaceuticals. The CEO Chris Gibson presents a lot about the company's platform, pipeline, partnerships, etc. He highlights 2023 achievements: acquisitions, NVIDIA collaboration, Tempus data, pipeline progress, etc. He also mentions upcoming catalysts. In the Q&A, there are questions about LOWE (Large Language Model Orchestrated Workflow Engine), NVIDIA collaboration, fibrosis program, CCM readout, business model, etc. We need to identify a positive current development that management highlights and analysts probe. The Q&A includes questions about LOWE, NVIDIA, fibrosis, CCM, etc. But does the Q&A add concrete operating detail beyond the prepared remarks? Let's look at specific exchanges. For example, the question about LOWE: "how do you plan to utilize LOWE either internally or as an external offering?" The answer talks about internal use, autonomous agents, and gives an example of using LLM scores to initiate new pre-programs. That seems to add some detail about how LOWE is used internally, but is it concrete operating detail? It mentions a plot of thousands of targets, using LLM scores to initiate programs. That is somewhat specific but not necessarily about current business activity like customers or volumes. Another question about NVIDIA: "what involvement will you have with NVIDIA in the near future and going forward?" The answer repeats the three areas: advanced computation, priority access, BioNeMo. It doesn't add much new beyond the prepared remarks. Question about fibrosis: "how is the asset you unlicensed differentiated and what are the first disease areas of focus?" The answer says they won't share the first disease area, but explains differentiation via complex assay, mentions molecule 1169575, etc. That adds some detail about the program, but is it a positive current development? It's a program in IND-enabling studies, so it's current progress. But does the Q&A add more than the prepared remarks? The prepared remarks already mentioned Target Epsilon in IND-enabling studies.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| FTAI | Fortress Transportation and Infrastructu | Q2 2024 | 2024-07-24 | A |
| FYBR | Frontier Communications Parent, Inc. | Q1 2024 | 2024-05-03 | B |
| TOL | Toll Brothers, Inc. | Q1 2024 | 2024-02-21 | A |
| GDDY | GoDaddy Inc. | Q4 2023 | 2024-02-13 | B+ |
| ZWS | Zurn Elkay Water Solutions Corporation | Q4 2023 | 2024-02-07 | B |
| TMUS | T-Mobile US, Inc. | Q4 2023 | 2024-01-25 | B |
| VCEL | Vericel Corporation | Q3 2023 | 2023-11-08 | A |
| WEAV | Weave Communications, Inc. | Q3 2023 | 2023-11-01 | B+ |
| MAC | The Macerich Company | Q3 2023 | 2023-10-31 | D |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| MNSO | MINISO Group Holding Limited | Q4 2023 | 2023-08-22 | A |
| PFGC | Performance Food Group Company | Q4 2023 | 2023-08-16 | B+ |
| SURG | SurgePays, Inc. | Q2 2023 | 2023-08-12 | D |
| EVLV | Evolv Technologies Holdings, Inc. | Q2 2023 | 2023-08-10 | B+ |
| TREX | Trex Company, Inc. | Q2 2023 | 2023-07-31 | B+ |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| NOW | ServiceNow, Inc. | Q2 2023 | 2023-07-26 | A |
| UTHR | United Therapeutics Corporation | Q1 2023 | 2023-05-03 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| MGM | MGM Resorts International | Q1 2023 | 2023-05-01 | A |
| EDU | New Oriental Education & Technology Grou | Q3 2023 | 2023-04-19 | B |
| PAYX | Paychex, Inc. | Q3 2023 | 2023-03-29 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| CUTR | Cutera, Inc. | Q3 2022 | 2022-11-05 | C |
| INMD | InMode Ltd. | Q3 2022 | 2022-10-27 | B+ |
| SHW | The Sherwin-Williams Company | Q2 2022 | 2022-07-27 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| APLE | Apple Hospitality REIT, Inc. | Q4 2021 | 2022-02-23 | B+ |
| DV | DoubleVerify Holdings, Inc. | Q3 2021 | 2021-11-11 | B |
| ENV | Envestnet, Inc. | Q3 2021 | 2021-11-08 | B+ |
| AMH | American Homes 4 Rent | Q3 2021 | 2021-11-05 | B+ |
| BIGC | BigCommerce Holdings, Inc. | Q3 2021 | 2021-11-04 | B+ |
| SPSC | SPS Commerce, Inc. | Q3 2021 | 2021-10-28 | A |
| INBK | First Internet Bancorp | Q3 2021 | 2021-10-21 | B+ |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| SNY | Sanofi | Q3 2018 | 2018-10-31 | B+ |
| GAIA | Gaia, Inc. | Q2 2018 | 2018-08-06 | B+ |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| VRTX | Vertex Pharmaceuticals Incorporated | Q1 2018 | 2018-04-26 | C+ |
| SNDR | Schneider National, Inc. | Q1 2018 | 2018-04-26 | A |
| ROKU | Roku, Inc. | Q4 2017 | 2018-02-21 | B+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| INTU | Intuit Inc. | Q3 2017 | 2017-05-23 | B+ |
| SAH | Sonic Automotive, Inc. | Q1 2017 | 2017-04-26 | C |
| FIVN | Five9, Inc. | Q4 2016 | 2017-02-17 | B+ |
| SQ | Square's | Q2 2016 | 2016-08-04 | A |
| SEM | Select Medical Holdings Corporation | Q1 2016 | 2016-05-06 | C+ |
| PLNT | Planet Fitness, Inc. | Q4 2015 | 2016-03-03 | B+ |
| BECN | Beacon Roofing Supply, Inc. | Q1 2016 | 2016-02-05 | B |
APLE · Q4 2021 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows a clear positive current development in the company's hotel portfolio recovery, particularly around Q1 2022 demand trends and operational metrics. In prepared remarks, Justin Knight and Liz Perkins highlight overall RevPAR improvement, leisure strength, and business travel recovery, but without granular February specifics.
MKC · Q2 2018 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES NO (Gate 2 fails because the Frank’s/French’s growth is repeatedly tied to specific large retailers, national accounts, and one major customer whose shelf-reset decisions and promotional activity are named or implied as key drivers; the transcript never establishes a broad, granular base of many independent counterparties whose small decisions are widening adoption.
GAIA · Q2 2018 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows a positive current development in organic subscriber growth and the member referral program. Prepared remarks note organic contributions over 40% and reduced marketing spend. Q&A provides additive details: specific referral mechanics (7-day free watch), ambassador program vs.